LCTX - Lineage Cell Therapeutics Inc
Close
0.8839
0.007 0.803%
Share volume: 442,000
Last Updated: Fri 30 Aug 2024 10:30:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.88
0.01
0.81%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-10 | 2023-03-09 | 2023-05-11 | 2023-08-10 | 2023-11-09 | 2024-03-07 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 135.922 M | 131.148 M | 123.664 M | 113.205 M | 111.688 M | 106.153 M | 101.019 M | 108.483 M | |
| Current Assets | 74.026 M | 68.509 M | 60.000 M | 49.655 M | 48.491 M | 43.481 M | 38.441 M | 45.716 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.289 M | 1.720 M | 1.828 M | 2.638 M | 2.123 M | 1.717 M | 2.204 M | 2.018 M | |
| Short Term Investments | 1.289 M | 1.720 M | 1.828 M | 2.638 M | 2.123 M | 1.717 M | 2.204 M | 2.018 M | |
| Total Receivables | 707.000 K | 434.000 K | 297.000 K | 203.000 K | 443.000 K | 432.000 K | 745.000 K | 77.000 K | |
| Current Cash | 72.030 M | 66.355 M | 57.875 M | 46.814 M | 45.925 M | 41.332 M | 35.492 M | 43.621 M | |
| Total Non-current Assets | 61.896 M | 62.639 M | 63.664 M | 63.550 M | 63.197 M | 62.672 M | 62.578 M | 62.767 M | |
| Property Plant Equipment | 3.869 M | 4.652 M | 5.673 M | 5.584 M | 5.310 M | 4.854 M | -1.113 M | 2.104 M | |
| Other Assets | 598.000 K | 591.000 K | 627.000 K | 635.000 K | 588.000 K | 552.000 K | 577.000 K | 596.000 K | |
| Intangible Assets | 46.757 M | 46.724 M | 46.692 M | 46.659 M | 46.627 M | 46.594 M | 46.562 M | 46.540 M | |
| Goodwill | 10.672 M | 10.672 M | 10.672 M | 10.672 M | 10.672 M | 10.672 M | 10.672 M | 10.672 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 135.922 M | 131.148 M | 123.664 M | 113.205 M | 111.688 M | 106.153 M | 101.019 M | 108.483 M | |
| Total liabilities | 53.075 M | 52.200 M | 50.325 M | 42.755 M | 39.021 M | 38.036 M | 37.600 M | 36.081 M | |
| Total current liabilities | 25.091 M | 22.739 M | 18.981 M | 17.225 M | 16.052 M | 15.881 M | 17.960 M | 16.890 M | |
| Accounts Payable | 2.589 M | 2.865 M | 2.393 M | 3.001 M | 2.187 M | 2.430 M | 2.050 M | 2.211 M | |
| Other liabilities | 25.778 M | 26.548 M | 27.727 M | 24.017 M | 21.688 M | 21.195 M | 18.693 M | 18.177 M | |
| Current long term debt | 29.000 K | 25.000 K | 36.000 K | 51.000 K | 54.000 K | 55.000 K | 52.000 K | 49.000 K | |
| Long term debt | 19.000 K | 16.000 K | 84.000 K | 133.000 K | 113.000 K | 97.000 K | 91.000 K | 79.000 K | |
| Other liabilities | 25.778 M | 26.548 M | 27.727 M | 24.017 M | 21.688 M | 21.195 M | 18.693 M | 18.177 M | |
| Minority interest | -1.348 M | -1.395 M | -1.403 M | -1.435 M | -1.409 M | -1.457 M | -1.396 M | -1.412 M | |
| Total Shareholder equity | 82.847 M | 78.948 M | 73.339 M | 70.450 M | 72.667 M | 68.117 M | 63.419 M | 72.402 M | |
| Common stock | 169.731 M | 169.786 M | 170.004 M | 170.127 M | 170.592 M | 174.868 M | 175.065 M | 182.909 M | |
| Retained earnings | -350.947 M | -357.016 M | -363.370 M | -367.742 M | -372.971 M | -380.081 M | -384.856 M | -391.398 M |